Rapid Optical Biosensing of SARS-CoV-2 Spike Proteins in Artificial Samples

Mohamad Sawan, Fieee, Frsc, Fcae, Feic, O.q., Ying Tao, Sumin Bian, Pengbo Wang, Hongyong Zhang, Wenwen Bi, Peixi Zhu, Mohamad SawanSensors 2022 · DOI

TL;DR

Researchers have developed a rapid, fiber-optic biosensor that can detect SARS-CoV-2 spike proteins (ECD and RBD) in artificial saliva and serum within 13 minutes. This new method offers a faster alternative to traditional nucleic acid tests, utilizing a novel signal amplification strategy with AMEC for improved sensitivity and a more environmentally friendly approach.

What Problem Does This Paper Address?

The ongoing COVID-19 pandemic necessitates rapid and accurate diagnostic tools for widespread surveillance and timely intervention. Current nucleic acid tests, while highly sensitive, often involve lengthy waiting times for results, hindering immediate public health responses. The SARS-CoV-2 virus's spike protein, particularly its extracellular domain (ECD) and receptor-binding domain (RBD), are key targets for detection as they are crucial for viral entry into human cells. Existing biosensing methods, while improving, still face challenges in achieving rapid detection with high sensitivity and robustness in complex biological matrices like saliva and serum. This paper aims to address the need for a faster, more efficient biosensing platform for SARS-CoV-2 spike proteins.

Methods

The core of this work is a fiber-optic biolayer interferometry (FO-BLI) biosensor. This technique relies on measuring changes in the refractive index at the fiber tip surface, which correlate with the binding of target molecules. The assay follows a sandwich immunoassay format:

  1. Antibody Immobilization: A biotinylated neutralizing antibody (MA-RBD) targeting the spike protein is immobilized onto streptavidin-coated optical fibers.
  2. Antigen Capture: The optical fibers are then exposed to samples containing SARS-CoV-2 ECD or RBD.
  3. Secondary Antibody Binding: A secondary antibody conjugated with horseradish peroxidase (HRP) binds to the captured antigen.
  4. Signal Amplification: This is where the novelty lies. The HRP enzyme catalyzes a reaction with a substrate to produce a precipitate, which increases the optical signal. The researchers compared two substrates:
  5. 3,3'-diaminobenzidine (DAB): A traditional substrate known for signal enhancement.
  6. 3-amino-9-ethylcarbazole (AMEC): A newer, potentially less toxic alternative. The AMEC-based approach demonstrated superior performance.

The researchers also addressed potential matrix effects from saliva and serum by using a high-salt diluent buffer, which helps minimize non-specific binding.

Datasets

The study used artificial samples including:

  • Artificial saliva
  • Healthy control serum

These samples were spiked with known concentrations of SARS-CoV-2 ECD and RBD, as well as other coronavirus proteins (SARS-CoV RBD, MERS-CoV S-protein, SARS-CoV-2 N-protein, and SARS-CoV-2 RBD (N501Y)) to evaluate specificity. No new benchmark datasets were introduced; rather, the performance was evaluated against these spiked artificial matrices.

Key Insights and Ideas

  • AMEC Outperforms DAB: The AMEC substrate provided a higher signal-to-noise ratio and lower background noise compared to DAB, making it a more effective signal enhancer for this FO-BLI system.
  • Environmental Friendliness: AMEC is presented as a more environmentally and human-friendly alternative to DAB, which has known toxicity concerns.
  • Rapid Detection in Complex Matrices: The FO-BLI biosensor successfully detected target proteins in artificial saliva and serum with minimal matrix interference, thanks to the high-salt buffer.
  • Potential for Automation and High Throughput: The fiber-optic nature of the sensor, coupled with the potential for multi-channel systems, suggests a pathway towards automated, high-throughput SARS-CoV-2 detection.
  • Flexibility for Variants: The antibody-based approach offers the potential to adapt the biosensor for detecting emerging SARS-CoV-2 variants by simply changing the capture antibody.

Key Results

  • Detection Time: The biosensor achieved a rapid sample-to-result time of 13 minutes.
  • Sensitivity (LoD):
    • SARS-CoV-2 ECD: 36 pM in artificial saliva and serum.
  • SARS-CoV-2 RBD: 12.5 pM in artificial saliva and serum.
  • Detection Ranges:
    • ECD: 36–1152 pM
    • RBD: 12.5–400 pM
  • Specificity: The biosensor showed no significant cross-reactivity with other tested coronavirus proteins, with only slight reactivity towards SARS-CoV-2 RBD (N501Y).
  • Signal Enhancement: AMEC resulted in a signal-to-noise ratio of 14.6, compared to 7.4 for DAB.
  • RSD: Relative standard deviation (RSD) values for RBD (12.5 pM) and ECD (36 pM) were 12.4% and 14.2%, respectively, indicating reliable quantification.

Limitations and Future Work

  • Clinical Validation: The study was conducted using artificial samples. The authors acknowledge that further studies are needed to improve sensitivity and validate the clinical utility of the biosensor using human samples.
  • Fiber Regeneration: While AMEC's solubility in alcohols and DMF suggests potential for fiber regeneration, this was not demonstrated in the current study.
  • Pseudovirus Optimization: The optimization for pseudovirus detection needs further investigation.
  • Sensitivity Improvement: While AMEC improved the signal-to-noise ratio, further work may be needed to push the absolute sensitivity limits even lower, especially for very low viral loads.

Summary updated

BibTeX
@article{oq2022rapid,
  author = {Mohamad Sawan, FIEEE, FRSC, FCAE, FEIC, O.Q. and Ying Tao and Sumin Bian and Pengbo Wang and Hongyong Zhang and Wenwen Bi and Peixi Zhu and Mohamad Sawan},
  title = {{Rapid Optical Biosensing of SARS-CoV-2 Spike Proteins in Artificial Samples}},
  journal = {Sensors},
  year = {2022},
  doi = {10.3390/s22103768},
}
Figure